Marina Biotech announces worldwide exclusive licensing agreement with Monsanto Marina Biotech (MRNA) announced that it has entered into an exclusive licensing agreement with Monsanto (MON) for Marina Biotech's delivery and chemistry technologies. Terms of the agreement were not disclosed.
News For MRNA;MON From The Last 14 Days
Check below for free stories on MRNA;MON the last two weeks.
Monsanto can execute another reinvention, says Citigroup Citigroup believes Monsanto is reinventing itself like it did when Roundup went off patent in the late 1990's by using the cash flow from the seeds business to get into new growth areas. Citi thinks management can execute the transition but admits the stock may be range-bound over the near-term. The firm keeps a Buy rating on Monsanto with a $146 price target.